(RTTNews) – Sinovac Biotech Ltd. (SVA), a biopharmaceuticals company in China, announced Tuesday that it has recently begun phase III clinical trials for its inactivated COVID-19 candidate vaccine evolved through Sinovac Life Sciences, or “CoronaVac” in Turkey. .
The Phase III clinical trial aims to verify the efficacy and protection of CoronaVac in Turkey and is intended to be a key examination for the approval of this product.
This phase III, randomized, double-blind, placebo-controlled case-controlled trial uses an adaptive design and all participants will be recruited step by step.
Initially, it will be decided randomly that 1,300 fitness care staff over the age of 18 to 59 get two doses of vaccine or placebo two weeks apart.
Sinovac noted that in months, its Phase I/II CoronaVac clinical trials in volunteer adults and the elderly were conducted in the Chinese provinces of Jiangsu and Hebei on April 16 and May 22, respectively.
According to the company, the candidate vaccine appears to be well tolerated for other doses and no serious adverse occasions related to the vaccine have been reported, demonstrating a protective profile for the candidate vaccine.
In addition to Turkey, Sinovac has partnered with several corporations outside China for Phase III efficacy studies.